Comparative Pharmacology
Head-to-head clinical analysis: GRISEOFULVIN versus MYIDYL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GRISEOFULVIN versus MYIDYL.
GRISEOFULVIN vs MYIDYL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binds to microtubular protein tubulin, disrupting mitotic spindle formation and inhibiting fungal cell mitosis. Also interferes with fungal nucleic acid synthesis and cell wall deposition.
c-Met/ALK inhibitor; inhibits receptor tyrosine kinases MET and ALK, blocking downstream signaling pathways including PI3K/AKT and RAS/RAF/MEK/ERK, leading to reduced tumor cell proliferation and angiogenesis.
500 mg orally once daily or 250 mg orally twice daily; microsize formulation: 500-1000 mg orally once daily; ultramicrosize formulation: 330-375 mg orally once daily. Administer with fatty meal to enhance absorption.
50 mg orally twice daily without regard to meals.
None Documented
None Documented
Clinical Note
moderateGriseofulvin + Estrone sulfate
"The metabolism of Estrone sulfate can be increased when combined with Griseofulvin."
Clinical Note
moderateGriseofulvin + Tranilast
"The risk or severity of adverse effects can be increased when Griseofulvin is combined with Tranilast."
Clinical Note
moderateGriseofulvin + Tolfenamic acid
"The risk or severity of adverse effects can be increased when Griseofulvin is combined with Tolfenamic acid."
Clinical Note
moderateGriseofulvin + Nimesulide
Terminal elimination half-life is 9 to 24 hours; clinically, it allows once or twice daily dosing.
Terminal elimination half-life is approximately 12 hours (range 10–14 hours) in adults with normal renal function; prolonged in renal impairment (up to 24–30 hours).
Primarily hepatic metabolism; less than 1% excreted unchanged in urine; metabolites excreted in urine (approximately 50%) and feces (approximately 36%) within 24 hours.
Primarily renal excretion as unchanged drug (~60%) and metabolites (~30%); biliary/fecal excretion accounts for ~10%.
Category D/X
Category C
Antifungal
Antifungal
"The risk or severity of adverse effects can be increased when Griseofulvin is combined with Nimesulide."